Indo-US Vaccine Action Programme Joint Statement extended till 2027.

October 14, 2022

The Department of Biotechnology (DBT) is implementing a focused bilateral collaborative programme known as the Indo-US Vaccine Action Programme (VAP), jointly with the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), USA, since July 1987.
The current five-year VAP Joint Statement has been extended till 2027.
Rajesh S. Gokhale, the Secretary, DBT along with the Indian delegation comprising senior officials from DBT is visiting the USA for the 34th Meeting of the Joint Working Group (JWG) of VAP and other scientific consultations.
The JWG provides oversight to VAP and comprises of Experts and the policy makers from India and US.
The meeting held at the NIH campus in Bethesda, Maryland in US. During the meeting, the Joint statement of Indo-US VAP has been signed by Dr. Rajesh S. Gokhale and Dr. Anthony Fauci, Director, NIAID considering the five year extension accorded to the programme till 2027.